Drugs & Aging

, Volume 22, Issue 8, pp 687–694

Causes of Syncope in Patients with Alzheimer’s Disease Treated with Donepezil

  • Philippe Bordier
  • Stephane Lanusse
  • Stephane Garrigue
  • Charlotte Reynard
  • Frederic Robert
  • Laurent Gencel
  • Alexia Lafitte
Original Research Article

Abstract

Introduction

Treatment of Alzheimer’s disease (AD) with cholinesterase inhibitors carries a theoretical risk of precipitating bradycardia. Though syncope occurs in patients with AD, its aetiology is unclear. The aim of this study was to determine the causes of syncope in patients with AD who were treated with donepezil and hospitalised for evaluation of syncope.

Methods

We studied 16 consecutive patients (12 women, 4 men) with AD aged 80 ± 4 years who were hospitalised for evaluation of syncope. All patients underwent staged evaluation, ranging from physical examination to electrophysiological testing.

Results

The mean dose of donepezil administered was 7.8 mg/day, and the mean duration of donepezil treatment at the time of syncope was 12 ± 8 months. A cause of syncope was identified in 69% of patients. Carotid sinus syndrome was observed in three patients, complete atrioventricular block in two patients, sinus node dysfunction in two patients, severe orthostatic hypotension in two patients and paroxysmal atrial fibrillation in one patient. A brain tumour was discovered in one patient. No cause of syncope was found in 31% of patients despite comprehensive investigation. Repetition of the investigations after discontinuation of donepezil was noncontributory.

Conclusion

In patients with AD treated with donepezil, a noninvasive evaluation identified a probable cause of syncope in over two-thirds of patients. Cardiovascular abnormalities were predominant. Noninvasive evaluation is recommended before discontinuing treatment with cholinesterase inhibitors in patients with AD and unexplained syncope.

References

  1. 1.
    Fox PJ, Kohatsu N, Max W, et al. Estimating the costs of caring for people with Alzheimer disease in California: 2000–2040. J Public Health Policy 2001; 22: 88–97PubMedCrossRefGoogle Scholar
  2. 2.
    Fratiglioni L, Launer LJ, Andersen K, et al. Incidence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000; 54: S10–5PubMedGoogle Scholar
  3. 3.
    Lobo A, Launer LJ, Fratiglioni L, et al. Prevalence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000; 54: S4–9PubMedCrossRefGoogle Scholar
  4. 4.
    Wolfson C, Wolfson DB, Asgharian M, et al. A reevaluation of the duration of survival after the onset of dementia. N Engl J Med 2001; 344: 1111–6PubMedCrossRefGoogle Scholar
  5. 5.
    Grutzendler J, Morris JC. Cholinesterase inhibitors for Alzheimer’s disease. Drugs 2001; 61: 41–52PubMedCrossRefGoogle Scholar
  6. 6.
    Shintani EY, Uchida KM. Donepezil: an anticholinesterase inhibitorfor Alzheimer’s disease. Am J Health Syst Pharm 1997; 54: 2805–10PubMedGoogle Scholar
  7. 7.
    Calvo-Romero JM, Ramos-Salado JL. Symptomatic sinus bradycardia associated with donepezil [in Spanish]. Rev Neurol 1999; 28: 1070–2PubMedGoogle Scholar
  8. 8.
    Shepherd G, Klein-Schwartz W, Edwards R. Donepezil overdose: a tenfold dosing error. Ann Pharmacother 1999; 33: 812–5PubMedCrossRefGoogle Scholar
  9. 9.
    Morganroth J, Graham S, Hartman R, et al. Electrocardiographic effects of rivastigmine. J Clin Pharmacol 2002; 42: 558–68PubMedCrossRefGoogle Scholar
  10. 10.
    Mant T, Troetel WM, Imbimbo BP. Maximum tolerated dose and pharmacodynamics of eptastigmine in elderly healthy volunteers. J Clin Pharmacol 1998; 38: 610–7PubMedGoogle Scholar
  11. 11.
    Greenberg SM, Tennis MK, Brown LB, et al. Donepezil therapy in clinical practice: a randomized crossover study. Arch Neurol 2000; 57: 94–9PubMedCrossRefGoogle Scholar
  12. 12.
    Bordier P, Garrigue S, Barold SS, et al. Significance of syncope in patients with Alzheimer’s disease treated with cholinesterase inhibitors. Europace 2003; 5: 429–31PubMedCrossRefGoogle Scholar
  13. 13.
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th rev. ed. Washington, DC: American Psychiatric Association, 1994Google Scholar
  14. 14.
    McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s disease. Neurology 1984; 34: 939–44PubMedCrossRefGoogle Scholar
  15. 15.
    Kapoor WN. Current evaluation and management of syncope. Circulation 2002; 106: 1606–9PubMedCrossRefGoogle Scholar
  16. 16.
    The Consensus Committee of the American Autonomic Society and the American Academy of Neurology. Consensus statement on the definition of orthostatic hypotension, pure autonomic failure and multiple system atrophy. Neurology 1996; 46: 1470CrossRefGoogle Scholar
  17. 17.
    Atkins D, Hanusa B, Sefcik T, et al. Syncope and orthostatic hypotension. Am J Med 1991; 91: 179–85PubMedCrossRefGoogle Scholar
  18. 18.
    Bass EB, Curtiss El, Arena VC, et al. The duration of Holter monitoring in patients with syncope. Is 24 hours enough? Arch Intern Med 1990; 150: 1073–8PubMedCrossRefGoogle Scholar
  19. 19.
    Brignole M, Alboni P, Benditt DG, et al. Guidelines on management (diagnosis and treatment) of syncope: update 2004. Eur Heart J 2004; 6: 467–537CrossRefGoogle Scholar
  20. 20.
    Almquist A, Gornick CC, Benson Jr DW, et al. Carotid sinus hypersensitivity: evaluation of the vasodepressor component. Circulation 1985; 71: 927–36PubMedCrossRefGoogle Scholar
  21. 21.
    Kenny RA, Richardson DA, Steen N, et al. Carotid sinus syndrome: a modifiable risk factor for nonaccidental falls in older adults (SAFE PACE). J Am Coll Cardiol 2001; 38: 1491–6PubMedCrossRefGoogle Scholar
  22. 22.
    Pavri BB, Ho RT. Syncope: identifying cardiac causes in older patients. Geriatrics 2003; 58: 26–31PubMedGoogle Scholar
  23. 23.
    Rees SA, Curtis MJ. Tacrine inhibits ventricular fibrillation induced by ischaemia and reperfusion and widens QT interval in rat. Cardiovasc Res 1993; 27: 453–8PubMedCrossRefGoogle Scholar
  24. 24.
    Savci V, Gurun MS, Cavun S, et al. Cardiovascular effects of centrally injected tetrahydroaminoacridine in conscious nor-motensive rats. Eur J Pharmacol 1998; 346: 35–41PubMedCrossRefGoogle Scholar
  25. 25.
    Fitzpatrick AP, Lee RJ, Epstein LM, et al. Effect of patient characteristics on the yield of prolonged baseline head-up tilt testing and the additional yield of drug provocation. Heart 1996; 76: 406–11PubMedCrossRefGoogle Scholar
  26. 26.
    McLaren AT, Allen J, Murray A, et al. Cardiovascular effects of donepezil in patients with dementia. Dement Geriatr Cogn Disord 2003; 15: 183–8PubMedCrossRefGoogle Scholar
  27. 27.
    Click RL, Gersh BJ, Sugrue DD, et al. Role of invasive electrophysiologic testing in patients with symptomatic bundle branch block. Am J Cardiol 1987; 59: 817–23PubMedCrossRefGoogle Scholar
  28. 28.
    Graham LA, Gray JC, Kenny RA. Comparison of provocative tests for unexplained syncope: isoprenaline and glyceryl trinitrate for diagnosing vasovagal syncope. Eur Heart J 2001; 22: 497–503PubMedCrossRefGoogle Scholar
  29. 29.
    Del Rosso A, Ungar A, Bartoli P, et al. Usefulness and safety of shortened head-up tilt testing potentiated with sublingual glyceryl trinitrate in older patients with recurrent unexplained syncope. J Am Geriatr Soc 2002; 50: 1324–8PubMedCrossRefGoogle Scholar
  30. 30.
    Kumar NP, Youde JH, Ruse C, et al. Responses to the prolonged head-up tilt followed by sublingual nitrate provocation in asymptomatic older adults. Age Ageing 2000; 29: 419–24PubMedCrossRefGoogle Scholar
  31. 31.
    Kapoor W, Snustad D, Peterson J, et al. Syncope in the elderly. Am J Med 1986; 80: 419–28PubMedCrossRefGoogle Scholar
  32. 32.
    Lipsitz LA, Wei JY, Rowe JW. Syncope in an elderly, institutionalised population: prevalence, incidence, and associated risk. Q J Med 1985; 55: 45–54PubMedGoogle Scholar
  33. 33.
    Kenny RA. Syncope in the elderly: diagnosis, evaluation, and treatment. J Cardiovasc Electrophysiol 2003; 14: S74–7PubMedCrossRefGoogle Scholar
  34. 34.
    Soteriades ES, Evans JC, Larson MG, et al. Incidence and prognosis of syncope. N Engl J Med 2002; 347: 878–85PubMedCrossRefGoogle Scholar
  35. 35.
    O’Shea D. Setting up a falls and syncope service for the elderly. Clin Geriatr Med 2002; 18: 269–78PubMedCrossRefGoogle Scholar
  36. 36.
    Rubenstein LZ, Josephson KR. The epidemiology of falls and syncope. Clin Geriatr Med 2002; 18: 141–58PubMedCrossRefGoogle Scholar
  37. 37.
    Kapoor WN, Karpf M, Wieand S, et al. A prospective evaluation and follow-up of patients with syncope. N Engl J Med 1983; 309: 197–204PubMedCrossRefGoogle Scholar
  38. 38.
    Hu T, Huang L, Cartwright WS. Evaluation of the costs of caring for the senile demented elderly: a pilot study. Gerontologist 1986; 26: 158–63PubMedCrossRefGoogle Scholar
  39. 39.
    Rice DP, Fox PJ, Max W, et al. The economic burden of Alzheimer’s disease care. Health Aff 1993; 12: 164–76CrossRefGoogle Scholar
  40. 40.
    Johnson N, Davis T, Bosanquet N. The epidemic of Alzheimer disease: how can we manage the costs? Pharmacoeconomics 2000; 18: 215–23PubMedCrossRefGoogle Scholar
  41. 41.
    Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer’s disease in the United States and the public health impact of delaying disease onset. Am J Public Health 1998; 88: 1337–42PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2005

Authors and Affiliations

  • Philippe Bordier
    • 1
  • Stephane Lanusse
    • 1
  • Stephane Garrigue
    • 1
  • Charlotte Reynard
    • 1
  • Frederic Robert
    • 1
  • Laurent Gencel
    • 1
  • Alexia Lafitte
    • 1
  1. 1.Cardiovascular Hospital of Haut-LevequeBordeaux-Pessac cedexFrance

Personalised recommendations